GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.